Key facts
- This page summarizes Carrie S. Cox's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Jan 2025, 16:19.
Carrie S. Cox - 02 Jan 2025 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)
- Reporting relationship
- Director
- Issuer ticker
- RNAC
- Reported as of
- 02 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jan 2025, 16:19:16 UTC
- Prior SEC filing
- 11 Jun 2024
- Next SEC filing
- 29 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Bartholomae, Attorney-in-Fact for Carrie Smith Cox
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Carrie S. Cox filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 06 Jan 2025.
Change
- Previous filing in this sequence was filed on 11 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNAC
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,600
- Change %
- +20%
- Price
- $0.000000
- Shares after
- 15,629
- Date
- 02 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNAC
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +8,000
- Change %
- Price
- $0.000000
- Shares after
- 8,000
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,000
- Exercise price
- $16.93
RNAC
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 8,266
- Date
- 02 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,266
- Exercise price
- $19.66
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026.
Footnote F2
On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
Footnote F3
This award vests in 36 equal monthly installments following the date of grant, so that it shall be fully vested on January 2, 2027.